Immunization with a highly attenuated replication-competent herpes simplex virus type 1 mutant, HF10, protects mice from genital disease caused by herpes simplex virus type 2

Frontiers in Microbiology

Volumn 3, Issue APR, 2012, Pages

  Luo, Chenhong ^a   Goshima, Fumi ^a   Kamakura, Maki ^a   Mutoh, Yoshifumi ^a   Iwata, Seiko ^a   Kimura, Hiroshi ^a   Nishiyama, Yukihiro ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Genital herpes; HSV 1; HSV 2; Live attenuated vaccine

Indexed keywords

EID: 84875657837     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2012.00158     Document Type: Article

References (51)

1. Arvin, A. M., and Gershon, A. A. (1996). Live attenuated varicella vaccine. Annu. Rev. Microbiol. 50, 59-100.
2. Belshe, R. B., Leone, P. A., Bernstein, D. I., Wald, A., Levin, M. J., Sta-pleton, J. T., Gorfinkel, I., Morrow, R. L., Ewell, M. G., Stokes-Riner, A., Dubin, G., Heineman, T. C., Schulte, J. M., Deal, C. D., and Herpevac Trial for Women. (2012). Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 366, 34-43.
3. Berkowitz, C., Moyal, M., Rosen-Wolff, A., Darai, G., and Becker, Y. (1994). Herpes simplex virus type 1 (HSV-1) UL56 gene is involved in viral intraperitoneal pathogenicity to immunocompetent mice. Arch. Virol 134,73-83.
4. Bernstein, D. I., Aoki, F. Y., Tyring, S. K., Stanberry, L. R., St-Pierre, C., Shafran, S. D., Leroux-Roels, G., Van Herck, K., Bollaerts, A., Dubin, G.,GlaxoSmithKline Herpes Vaccine Study Group. (2005). Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin. Infect. Dis. 40,1271-1281.
5. Brans, R., Akhrameyeva, N. V., and Yao, F. (2009). Prevention of genital herpes simplex virus type 1 and 2 disease in mice immunized with a gD-expressing dominant-negative recombinant HSV-1. J. Invest. Der-matol. 129, 2470-2479.
6. Brans, R., Eriksson, E., and Yao, F. (2008). Immunization with a dominant-negative recombinant HSV type 1 protects against HSV-1 skin disease in guinea pigs. J. Invest. Dermatol. 128, 2825-2832.
7. Bryson, Y., Dillon, M., Bernstein, D. I., Radolf, J., Zakowski, P., and Garratty, E. (1993). Risk of acquisition of genital herpes simplex virus type 2 in sex partners of persons with genital herpes: a prospective couple study. J. Infect. Dis. 167, 942-946.
8. Cappel, R. (1976). Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Arch. Virol. 52, 29-35.
9. Celum, C., Wald, A., Hughes, J., Sanchez, J., Reid, S., Delany-Moretlwe, S., Cowan, F., Casapia, M., Ortiz, A., Fuchs, J., Buchbinder, S., Koblin, B., Zwerski, S., Rose, S., Wang, J., Corey, L., (2008). Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371, 2109-2119, HPTN 039 Protocol Team
10. Corey, L., and Spear, P. G. (1986). Infections with herpes simplex viruses (2). N. Engl.J. Med. 314, 749-757.
11. Eis-Hubinger, A. M., Schmidt, D. S., and Schneweis, K. E. (1993). Anti-glycoprotein B monoclonal antibody protects T cell-depleted mice against herpes simplex virus infection by inhibition of virus replication at the inoculated mucous membranes. J. Gen. Virol. 74(Pt 3), 379-385.
12. Freeman, E. E., Weiss, H. A., Glynn, J. R., Cross, P. L., Whitworth, J. A., and Hayes, R. J. (2006). Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20, 73-83.
13. Fujimoto, Y., Mizuno, T., Sugiura, S., Goshima, F., Kohno, S., Nakashima, T., and Nishiyama, Y. (2006). Intra-tumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 126,1115-1117.
14. Goshima, F., Watanabe, D., Takakuwa, H., Wada, K., Daikoku, T., Yamada, M., and Nishiyama, Y. (2000). Herpes simplex virus UL17 protein is associated with B capsids and colocalizes with ICP35 and VP5 in infected cells. Arch. Virol 145,417-426.
15. Iijima, N., Linehan, M. M., Zamora, M., Butkus, D., Dunn, R., Kehry, M. R., Laufer, T. M., and Iwasaki, A. (2008). Dendritic cells and B cells maximize mucosal Th1 memory response to herpes simplex virus. J. Exp. Med. 205,3041-3052.
16. Jiang, Y. M., Daikoku, T., Yamamoto, M., Morishima, T., and Nishiyama, Y. (1995). Growth and cytopathogenic-ity of herpes simplex virus in a macrophage cell line, RAW264: a good indicator of intraperitoneal pathogenicity. Microbiol Immunol. 39,905-909.
17. Jones, C., Inman, M., Peng, W., Henderson, G., Doster, A., Perng, G. C., and Angeletti, A. K. (2005). The herpes simplex virus type 1 locus that encodes the latency-associated transcript enhances the frequency of encephalitis in male BALB/c mice. J. Virol. 79,14465-14469.
18. Kapiga, S. H., Sam, N. E., Bang, H., Ni, Q., Ao, T. T., Kiwelu, I., Chiduo, S., Ndibe, U., Seage, G. III, Coplan, P., Shao, J., Rosenberg, Z. F., and Essex, M. (2007). The role of herpes simplex virus type 2 and other genital infections in the acquisition of HIV-1 among high-risk women in northern Tanzania. J. Infect. Dis. 195, 1260-1269.
19. Kato, K., Daikoku, T., Goshima, F., Kume, H., Yamaki, K., and Nishiyama, Y. (2000). Synthesis, sub-cellular localization and VP16 interaction of the herpes simplex virus type 2 UL46 gene product. Arch. Virol. 145,2149-2162.
20. Kieff, E., Hoyer, B., Bachenheimer, S., and Roizman, B. (1972). Genetic relatedness of type 1 and type 2 herpes simplex viruses. J. Virol. 9, 738-745.
21. Kimata, H., Imai, T., Kikumori, T., Teshigahara, O., Nagasaka, T., Goshima, F., Nishiyama, Y., and Nakao, A. (2006). Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer. Ann. Surg. Oncol. 13, 1078-1084.
22. Koshizuka, T., Goshima, F., Takakuwa, H., Nozawa, N., Daikoku, T., Koiwai, O., and Nishiyama, Y. (2002). Identification and characterization of the UL56 gene product of herpes simplex virus type 2. J. Virol. 76, 6718-6728.
23. Koshizuka, T., Takakuwa, H., Goshima, F., Murata, T., and Nishiyama, Y. (2001). The US11 gene product of herpes simplex virus has intercellular trafficking activity. Biochem. Biophys. Res. Commun. 288, 597-602.
24. Lafferty, W. E., Downey, L., Celum, C., and Wald, A. (2000). Herpes simplex virus type 1 as a cause of genital herpes: impact on surveillance and prevention. J. Infect. Dis. 181, 1454-1457.
25. Lasky, L. A., and Dowbenko, D. J. (1984). DBA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2. DNA 3, 23-29.
26. Lu, Z., Brans, R., Akhrameyeva, N. V., Murakami, N., Xu, X., and Yao, E (2009). High-level expression of gly-coprotein D by a dominant-negative HSV-1 virus augments its efficacy as a vaccine against HSV-1 infection. J. Invest. Dermatol. 129, 1174-1184.
27. Malvy, D., Halioua, B., Lancon, F., Rez-vani, A., Bertrais, S., Chanzy, B., Daniloski, M., Ezzedine, K., Malkin, J. E., Morand, P., De Labareyre, C., Hercberg, S., El Hasnaoui, A. (2005). Epidemiology of genital herpes simplex virus infections in a community-based sample in France: results of the HERPIMAX study. Sex. Transm. Dis. 32, 499-505.
28. McDermott, M. R., Brais, L. J., and Evelegh, M. J. (1990). Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2. J. Gen. Virol. 71 (Pt 7), 1497-1504.
29. Mertz, G. J., Benedetti, J., Ashley, R., Selke, S. A., and Corey, L. (1992). Risk factors for the sexual transmission of genital herpes. Ann. Intern. Med. 116, 197-202.
30. Miller, C. S., Danaher, R. J., and Jacob, R. J. (1998). Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence. Crit. Rev. Oral Biol. Med. 9,541-562.
31. Mori, I., Liu, B., Goshima, F., Ito, H., Koide, N., Yoshida, T., Yokochi, T., Kimura, Y., and Nishiyama, Y. (2005). HF10, an attenuated herpes simplex virus (HSV) type 1 clone, lacks neuroinvasiveness and protects mice against lethal challenge with HSV types 1 and 2. Microbes Infect. 7,1492-1500.
32. Muller, W. J., Dong, L., Vilalta, A., Byrd, B., Wilhelm, K. M., McClurkan, C. L., Margalith, M., Liu, C., Kaslow, D., Sidney, J., Sette, A., and Koelle, D. M. (2009). Herpes simplex virus type 2 tegument proteins contain sub-dominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J. Gen. Virol. 90(Pt 5), 1153-1163.
33. Nakanishi, Y., Lu, B., Gerard, C., and Iwasaki, A. (2009). CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462, 510-513.
34. Nakao, A., Takeda, S., Shimoyama, S., Kasuya, H., Kimata, H., Teshiga-hara, O., Sawaki, M., Kikumori, T., Kodera, Y., Nagasaka, T., Goshima, F., Nishiyama, Y., and Imai, T. (2007). Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer. Curr. Cancer Drug Targets 7, 169-174.
35. Nieuwenhuis, R. F., van Doornum, G. J., Mulder, P. G., Neumann, H. A., and van der Meijden, W. I. (2006). Importance of herpes simplex virus type-1 (HSV-1) in primary genital herpes. Acta Derm. Venereol. 86, 129-134.
36. Nishiyama, Y., Kimura, H., and Daikoku, T. (1991). Complementary lethal invasion of the central nervous system by nonneuroinvasive herpes simplex virus types 1 and 2. J. Virol. 65, 4520-4524.
37. Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Sim-berkoff, M. S., Gershon, A. A., Davis, L. E., Weinberg, A., Boardman, K. D., Williams, H. M., Zhang, J. H., Peduzzi, P. N., Beisel, C. E., Morrison, V A., Guatelli, J. C., Brooks, P. A., Kauffman, C. A., Pachucki, C. T., Neuzil, K. M., Betts, R. F., Wright, P. E, Griffin, M. R., Brunell, P., Soto, N. E., Marques, A. R., Keay, S. K., Goodman, R. P., Cotton, D. J., Gnann, J.W. Jr., Loutit, J., Holodniy, M., Kei-tel, W. A., Crawford, G. E., Yeh, S. S., Lobo, Z., Toney, J. F., Greenberg, R. N., Keller, P. M., Harbecke, R., Hayward, A. R., Irwin, M. R., Kyri-akides, T. C., Chan, C. Y., Chan, I. S., Wang, W. W., Annunziato, P. W., Silber, J. L., and Shingles Prevention Study Group. (2005). A vaccine to prevent herpes zoster and posther-petic neuralgia in older adults. N. Engl. J. Med. 352, 2271-2284.
38. Peng, W., Henderson, G., Inman, M., BenMohamed, L., Perng, G. C., Wechsler, S. L., and Jones, C. (2005). The locus encompassing the latency-associated transcript of herpes simplex virus type 1 interferes with and delays interferon expression in productively infected neuroblas-toma cells and trigeminal Ganglia of acutely infected mice. J. Virol. 79, 6162-6171.
39. Rosen-Wolff, A., Lamade, W., Berkowitz, C., Becker, Y., and Darai, G. (1991). Elimination of UL56 gene by insertion of LacZ cassette between nucleotide position 116030 to 121753 of the herpes simplex virus type 1 genome abrogates intraperitoneal pathogenicity in tree shrews and mice. Virus Res. 20,205-221.
40. Stanberry, L. R. (2004). Clinical trials of prophylactic and therapeutic herpes simplex virus vaccines. Herpes 11(Suppl. 3), 161A-169A.
41. Stanberry, L. R., Cunningham, A. L., Mindel, A., Scott, L. L., Spruance, S. L., Aoki, E Y., Lacey, C. J. (2000). Prospects for control of herpes simplex virus disease through immunization. Clin. Infect. Dis. 30, 549-566.
42. Stanberry, L. R., Spruance, S. L., Cunningham, A. L., Bernstein, D. I., Mindel, A., Sacks, S., Tyring, S., Aoki, E Y, Slaoui, M., Denis, M., Vande-papeliere, P., Dubin, G., Glax-oSmithKline Herpes Vaccine Efficacy Study Group. (2002). Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347, 1652-1661.
43. Swenson, S. L., McMillen, J., and Hill, H. T. (1993a). Diagnostic compatibility of a thymidine kinase, inverted repeat, gI, and gpX modified live gene-deleted PRV vaccine with three differential ELISAs. J. Vet. Diagn. Invest. 5, 347-350.
44. Swenson, S. L., McMillen, J., and Hill, H. T. (1993b). Evaluation of the safety and efficacy of a thymidine kinase, inverted repeat, gI, and gpX gene-deleted pseudorabies vaccine. J. Vet. Diagn. Invest. 5, 341-346.
45. Tao, G., Kassler, W J., and Rein, D. B. (2000). Medical care expenditures for genital herpes in the United States. Sex. Transm. Dis. 27, 32-38.
46. Ushijima, Y., Luo, C., Goshima, F., Yamauchi, Y., Kimura, H., and Nishiyama, Y (2007). Determination and analysis of the DNA sequence of highly attenuated herpes simplex virus type 1 mutant HF10, a potential oncolytic virus. Microbes Infect. 9, 142-149.
47. Van de Walle, G. R., Favoreel, H. W., Nauwynck, H. J., and Pensaert, M. B. (2003). Antibody-induced internal-ization of viral glycoproteins and gE-gI Fc receptor activity protect pseudorabies virus-infected monocytes from efficient complement-mediated lysis. J. Gen. Virol. 84(Pt 4), 939-948.
48. Watson-Jones, D., Weiss, H. A., Rusi-zoka, M., Changalucha, J., Baisley, K., Mugeye, K., Tanton, C., Ross, D., Everett, D., Clayton, T., Balira, R., Knight, L., Hambleton, I., Le Goff, J., Belec, L., Hayes, R., HSV Trial Team, and Steering and Data Monitoring Committees. (2008). Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N. Engl. J. Med. 358,1560-1571.
49. Whitley, R. J., and Roizman, B. (2001). Herpes simplex virus infections. Lancet 357, 1513-1518.
50. Xu, F., Sternberg, M. R., Kottiri, B. J., McQuillan, G. M., Lee, E K., Nahmias, A. J., Berman, S. M., and Markowitz, L. E. (2006). Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 296, 964-973.
51. + T cells accumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J. Exp. Med. 204, 595-603.